מונטהלוקאסט טבע ® 4 מ"ג

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

MONTELUKAST AS SODIUM 4 MG

Disponible depuis:

TEVA PHARMACEUTICAL INDUST.LTD

Code ATC:

R03DC03

forme pharmaceutique:

CHEWABLE TABLETS

Mode d'administration:

PER OS

Fabriqué par:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Groupe thérapeutique:

MONTELUKAST

indications thérapeutiques:

Montelukast Teva is indicated in pediatric patients 2 to 5 years of age for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. Montelukast Teva is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. Montelukast Teva and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. Montelukast Teva is indicated for the relief of symptoms of seasonal allergic rhinitis in pediatric patients 2 to 5 years of age and older.

Date de l'autorisation:

2010-06-01